戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              T. vaginalis adhered to hVECs and produced severe cytoto
2                                              T. vaginalis and Tetratrichomonas gallinarum (both repre
3                                              T. vaginalis ASR is an increasingly utilized assay that
4                                              T. vaginalis contains two HSP70 sequences, one Mt-like a
5                                              T. vaginalis detection rate in males was 6.6%, with no d
6                                              T. vaginalis DNA was stable in specimens stored without
7                                              T. vaginalis extract was subjected to hydrophobic chroma
8                                              T. vaginalis has the coding capacity to produce an activ
9                                              T. vaginalis HPP forms an approximately 100 kDa homodime
10                                              T. vaginalis infection is strongly associated with an in
11                                              T. vaginalis infection was identified in 6.0% (16/268) o
12                                              T. vaginalis is the most common sexually transmitted inf
13                                              T. vaginalis may alter the vaginal microbiota in a manne
14                                              T. vaginalis may be endemic in this community of African
15                                              T. vaginalis PNP thus belongs to the family of bacterial
16                                              T. vaginalis prevalence by culture (InPouch; Biomed) was
17                                              T. vaginalis prevalence differed by race/ethnicity, with
18                                              T. vaginalis prevalence ranged from 5.4% in family plann
19                                              T. vaginalis research entered the age of genomics with t
20                                              T. vaginalis was detected more often in men with wet-mou
21                                              T. vaginalis was more prevalent than C. trachomatis or N
22                                              T. vaginalis was most prevalent in women who were 36 to
23                                              T. vaginalis was the predominant sexually transmitted ag
24 is study, we examined the propensities of 26 T. vaginalis strains to bind to and lyse prostate (BPH-1
25                      Vaginal samples from 30 T. vaginalis-infected women were matched by Nugent score
26 ere matched by Nugent score to those from 30 T. vaginalis-uninfected women.
27 ere observed using approximately 2.5 x 10(8) T. vaginalis cells and 350 volts, 960 microFd for electr
28 nts, 858 pharyngeal specimens yielded a 2.9% T. vaginalis detection rate compared with 2.1% for N. go
29                                            A T. vaginalis cDNA expression library was screened with p
30      The SLPI level was reduced by >50% in a T. vaginalis load-dependent manner.
31 lated in vitro by the catalytic subunit of a T. vaginalis protein kinase A, TvPKAc.
32                         The average age of a T. vaginalis-infected male (39.9 years) was significantl
33 kely as women with fewer partners to acquire T. vaginalis (hazard ratio, 4.3; 95% CI, 2.0-9.4).
34  acquired N. gonorrhoeae, and 12.8% acquired T. vaginalis); among 1183 men, 14.7% had 1 or more new i
35 tection of T. vaginalis was developed to add T. vaginalis infection to the growing list of STDs that
36  health care system was performed to address T. vaginalis prevalence in males.
37 s a potential chemotherapeutic agent against T. vaginalis.
38 rt the potential for a human vaccine against T. vaginalis infection that could also influence the inc
39                                The aggregate T. vaginalis detection rate trended higher than that of
40                                          All T. vaginalis pharyngeal detections were confirmed by TMA
41 second ATV TMA assay, utilizing an alternate T. vaginalis primer and probe set, was performed on all
42 nin-labeled ELISA for detection of amplified T. vaginalis DNA from urine, the sensitivity and specifi
43 rachomatis, 11.6%; N. gonorrhoeae, 2.4%; and T. vaginalis, 1.7%.
44 The observation that the two diplomonads and T. vaginalis share the same unusual GK and GPI is consis
45 nt with oral metronidazole is effective, and T. vaginalis DNA disappears rapidly after treatment.
46                        The M. genitalium and T. vaginalis detection rates among 755 patients at urban
47 ificantly higher than the N. gonorrhoeae and T. vaginalis infection rates.
48 mens for C. trachomatis, N. gonorrhoeae, and T. vaginalis TMA screening.
49 italium, C. trachomatis, N. gonorrhoeae, and T. vaginalis were 100, 70, 67, and 20%, respectively.
50 o detect C. trachomatis, N. gonorrhoeae, and T. vaginalis).
51 inal microbiota in T. vaginalis-infected and T. vaginalis-uninfected patients among women with normal
52  (CRS) comprised of wet-mount microscopy and T. vaginalis culture.
53                           C. trachomatis and T. vaginalis infection increase the susceptibility to SH
54 n due to N. gonorrhoeae, C. trachomatis, and T. vaginalis were 3.48, 4.55, and 1.32 cases per 100 per
55                                       Aptima T. vaginalis assay performance was determined for each s
56                                       Aptima T. vaginalis clinical sensitivity and specificity were,
57                                       Aptima T. vaginalis performance levels were similar in asymptom
58 ated the performance of the automated Aptima T. vaginalis assay for detecting T. vaginalis in 1,025 a
59  hybridization assay to the Gen-Probe Aptima T. vaginalis (ATV) transcription-mediated amplification
60 were tested by the TVQ assay, and the Aptima T. vaginalis (ATV) assay was performed using clinician-c
61 dates the clinical performance of the Aptima T. vaginalis assay for screening asymptomatic and sympto
62 T. vaginalis infection in HIV-endemic areas, T. vaginalis control may have a substantial impact on pr
63 th care professionals can consider TMA-based T. vaginalis screening for a wide age range of patients;
64 re we describe the performance of the new BD T. vaginalis Qx (TVQ) amplified DNA assay, which can be
65 emi-conservative genomic arrangement between T. vaginalis isolates.
66 nfection, as well as the association between T. vaginalis infection and increased transmission of and
67    We concluded that the interaction between T. vaginalis and hVECs is both cell specific (limited to
68 4 (55%) were introital, were tested for both T. vaginalis DNA and viable microorganisms using the 5'
69     (ii) Activation of local immune cells by T. vaginalis in the presence of infectious HIV-1 might l
70 nd relative light unit (RLU) data yielded by T. vaginalis ASR.
71 fe, aluminum hydroxide-adjuvanted whole-cell T. vaginalis vaccine for efficacy in a BALB/c mouse mode
72                                 A whole-cell T. vaginalis vaccine was administered subcutaneously to
73   Together, these data indicate that chronic T. vaginalis infections may result in TvMIF-driven infla
74                          In all comparisons, T. vaginalis PCR performed better than routine diagnosti
75 us and Neisseria gonorrhoeae with concurrent T. vaginalis infection.
76 mplification test (NAAT) were used to detect T. vaginalis.
77        The mean age of women with detectable T. vaginalis (30.6) was significantly higher than those
78                   In females with detectable T. vaginalis, codetection of Chlamydia trachomatis and N
79 tter than wet mount (P = 0.004) and detected T. vaginalis in samples that required 48 to 72 h of incu
80 ated Aptima T. vaginalis assay for detecting T. vaginalis in 1,025 asymptomatic and symptomatic women
81 eement between PCR and culture for detecting T. vaginalis.
82 nge of pathogenic properties among different T. vaginalis strains, all strains show strict contact-de
83 d among the 68 isolates, revealing a diverse T. vaginalis population.
84                                cDNA encoding T. vaginalis PNP was isolated by complementation of an E
85 er, contrary to that typical for eukaryotes, T. vaginalis spliceosomal snRNAs lack a cap and may cont
86  start site of transcription in all examined T. vaginalis genes.
87                                 All examined T. vaginalis introns have a highly conserved 12-nt 3' sp
88 taining 5' untranslated regions of expressed T. vaginalis genes was searched for overrepresented DNA
89 ifferent dsRNA molecules obtained from a few T. vaginalis isolates has suggested that more than one v
90     The presence of CD4(+) T cells following T. vaginalis infection can potentially increase suscepti
91 .74 (95% confidence interval, 1.25-6.00) for T. vaginalis-positive cases.
92  is a new point-of-care diagnostic assay for T. vaginalis that uses an immunochromatographic capillar
93  extraurogenital sources into assessment for T. vaginalis detection may identify additional symptomat
94 Aptima Trichomonas vaginalis assay; ATV) for T. vaginalis were compared with the Affirm VPIII Trichom
95 eplacement technology has been developed for T. vaginalis.
96 > or =2.0 and < or =1.5 were established for T. vaginalis-positive and -negative cutoffs, respectivel
97 netic markers with clinical implications for T. vaginalis infections.
98                             Until a NAAT for T. vaginalis is commercially available, a stepwise appro
99     Vaginal-swab specimens were obtained for T. vaginalis culture, wet mount, and rapid testing.
100 I agents) and 26.1% were solely positive for T. vaginalis (P < 0.0002 versus C. trachomatis).
101  Fifty-one women (38%) screened positive for T. vaginalis at baseline.
102  N. gonorrhoeae, 26 (5.2%) were positive for T. vaginalis, and 47 (9.5%) were positive for M. genital
103  Overall, 5.1% of subjects were positive for T. vaginalis.
104 rmy medical clinic were culture positive for T. vaginalis.
105 total samples tested, 6.6% were positive for T. vaginalis.
106 owever, first-void urine detection rates for T. vaginalis and C. trachomatis within this age demograp
107 matic or symptomatic, should be screened for T. vaginalis.
108 hral swab and first-void urine screening for T. vaginalis within a regional health care system was pe
109 ssay in urethral swabs, urine, and semen for T. vaginalis detection in male sexual partners of women
110 vely from both men and women were tested for T. vaginalis DNA with both the FRET-based assay and a pr
111 d be evaluated with more-sensitive tests for T. vaginalis, preferably NAATs, if microscopy is negativ
112 ening asymptomatic and symptomatic women for T. vaginalis infection.
113 e amplified the beta-fructofuranosidase from T. vaginalis cDNA and cloned it into an Escherichia coli
114  binding of T. foetus to BVECs; the LPG from T. vaginalis and a variety of other glycoconjugates did
115  information a PCR product was obtained from T. vaginalis gDNA and used to isolate corresponding cDNA
116 we have isolated an Inr-binding protein from T. vaginalis.
117        A lytic factor (LF) was purified from T. vaginalis, and the molecular characteristics of LF we
118                                 Furthermore, T. vaginalis LPG (but not LPG from Tritrichomonas foetus
119                              Combined-gender T. vaginalis detection rate (9.1%) was significantly gre
120 cquired STIs included chlamydia, gonorrhoea, T. vaginalis and syphilis with rapid plasma reagin >/=1:
121  and 0.24% for C. trachomatis/N. gonorrhoeae/T. vaginalis and highest in women <30 years old.
122 rachomatis/N. gonorrhoeae and N. gonorrhoeae/T. vaginalis, and 0.24% for C. trachomatis/N. gonorrhoea
123                                         High T. vaginalis prevalence in all age groups suggests that
124                                       Higher T. vaginalis prevalence in women of >40 years is probabl
125 st levels observed in those with the highest T. vaginalis loads.
126                                  The highest T. vaginalis prevalence was in women >/= 40 years old (>
127                        Eight DRP homologues [T. vaginalis DRPs (TvDRPs)], which can be grouped into 3
128                                     However, T. vaginalis is disproportionality under studied, especi
129                                          (i) T. vaginalis disruption of urogenital epithelial monolay
130 ed daily with a light microscope to identify T. vaginalis.
131 d detect beta-fructofuranosidase activity in T. vaginalis cell lysates.
132 bacteria, in some proteobacteria and also in T. vaginalis, a Type II amitochondriate protist.
133 etic analysis and assess the role of AP65 in T. vaginalis adherence, we silenced expression of ap65 u
134 me course following the expression of CAT in T. vaginalis transient transformants revealed the highes
135 ce of a plasminogen-binding alpha-enolase in T. vaginalis.
136 o both double and single Inr motifs found in T. vaginalis genes and that binding requires the conserv
137 emonstrate that the conserved motif found in T. vaginalis protein-encoding genes is an Inr promoter e
138 , catalyzing the first step of glycolysis in T. vaginalis, is different from that of the enzyme perfo
139 sms for the regulation of cysteine levels in T. vaginalis, we have characterized enzymes of the merca
140 owed divergence of the vaginal microbiota in T. vaginalis-infected and T. vaginalis-uninfected patien
141  hypothesized that the vaginal microbiota in T. vaginalis-infected women differs from that in T. vagi
142 be grouped into 3 subclasses, are present in T. vaginalis.
143 biotic Trichomonasvirus, highly prevalent in T. vaginalis clinical isolates, is sensed by the human e
144                            Core promoters in T. vaginalis appear to consist solely of a highly conser
145  demonstrate antisense RNA gene silencing in T. vaginalis to study the contribution of specific genes
146 aginalis-infected women differs from that in T. vaginalis-uninfected women.
147  median of 566 days, there were 806 incident T. vaginalis infections (23.6/100 person-years), and 265
148             A control strategy that includes T. vaginalis screening in nonclinical settings and rapid
149                                    Increased T. vaginalis detection was derived from female urine spe
150 fect on mammalian PNPs, was shown to inhibit T. vaginalis PNP with a K(is) of 2.3 microM by competing
151 nal leukocytosis, and recurrent (vs initial) T. vaginalis infection, with the lowest levels observed
152 ools and approaches available to interrogate T. vaginalis biology, with an emphasis on recent advance
153 ave introduced three heterologous genes into T. vaginalis by electroporation and have used the 5' and
154 This warrants a more thorough review of male T. vaginalis incidence.
155   Our data reveal a complex structure, named T. vaginalis lipoglycan (TvLG), that differs markedly fr
156 ned adhesive properties equal to the natural T. vaginalis AP33.
157 ron of P270 was evident among virus-negative T. vaginalis isolates or virus-negative progeny trichomo
158                          A total of 38.1% of T. vaginalis-positive pharyngeal specimens were derived
159                    All strains (15 of 15) of T. vaginalis tested were successfully detected by PCR gi
160                   Changes in MST activity of T. vaginalis in response to variation in the supply of e
161 act in the surface expression of adhesins of T. vaginalis organisms.
162             Steady-state kinetic analysis of T. vaginalis PNP-catalyzed reactions gave K(m)'s of 31.5
163              We have shown an association of T. vaginalis with basement membrane extracellular matrix
164  of hybridomas that inhibited the binding of T. vaginalis organisms to immobilized FN was identified.
165 the incidence and increased the clearance of T. vaginalis infection and induced both systemic and loc
166                              Coincubation of T. vaginalis isolates with acutely HIV-1-infected periph
167 , accurate, and high-throughput detection of T. vaginalis and may prove useful in clinical settings a
168 richomonosis was defined as the detection of T. vaginalis by direct microscopy and/or culture from ei
169  reported in females, TMA-based detection of T. vaginalis can be a routine constituent within a compr
170 xisting PCR method for specific detection of T. vaginalis DNA into a rapid real-time PCR assay based
171 a sensitive PCR assay, reliable detection of T. vaginalis in male partners required multiple specimen
172 ive and specific PCR assays for detection of T. vaginalis in urine, a noninvasive specimen, and devel
173 he exclusive use of urine-based detection of T. vaginalis is not appropriate in women.
174 to evaluate urine-based PCR for detection of T. vaginalis using a combined reference standard of wet
175                       PCR-based detection of T. vaginalis using vaginal specimens may provide an alte
176 ng vaginal swab samples for the detection of T. vaginalis was developed to add T. vaginalis infection
177 hniques in urine specimen-based detection of T. vaginalis was highly sensitive and revealed a prevale
178 l and cervical specimen-derived detection of T. vaginalis within African American majority geographic
179 d amplification (TMA) assay for detection of T. vaginalis.
180                             The diagnosis of T. vaginalis infection by PCR is a sensitive and specifi
181 er culture or wet mount for the diagnosis of T. vaginalis infections.
182  can be expected to improve the diagnosis of T. vaginalis, especially where microscopy and culture ar
183 lphaMPP and betaMPP before the divergence of T. vaginalis and mitochondria-bearing lineages.
184                                The effect of T. vaginalis isolates on HIV-1 passage through polarized
185 t to the monolayer disruption, the effect of T. vaginalis on HIV-1 replication was not isolate depend
186 ess, surface-associated glycolytic enzyme of T. vaginalis.
187  and may be an important virulence factor of T. vaginalis mediating the destruction of host cells and
188 ndicate a role for a TvDRP in the fission of T. vaginalis hydrogenosomes, similar to that described f
189 onserved region in the beta-tubulin genes of T. vaginalis.
190 Cluster analysis revealed 2 unique groups of T. vaginalis-infected women.
191                             The incidence of T. vaginalis infection is high among adolescent women; u
192 norrhoeae PCR assay allowed incorporation of T. vaginalis PCR diagnosis into routine clinical testing
193  F-dAdo and F-Ade exert strong inhibition of T. vaginalis growth with estimated IC(50) values of 106
194 rrying out studies to identify inhibitors of T. vaginalis PNP (TvPNP), we discovered that the nontoxi
195 ng a single, agar-cloned clinical isolate of T. vaginalis, confirming the natural capacity for concur
196               Different clinical isolates of T. vaginalis caused damage to cultured cells at differen
197 ixty-eight historical and recent isolates of T. vaginalis were sampled from the American Type Culture
198 s strains, from 4 other clinical isolates of T. vaginalis.
199 ying and treating females with low levels of T. vaginalis infection (before they become wet mount pos
200  used to screen a cDNA expression library of T. vaginalis.
201                     The kinetic mechanism of T. vaginalis PNP-catalyzed reactions, determined by prod
202  to the pathogenesis and disease outcomes of T. vaginalis infections of the human genital mucosa.
203 death may be involved in the pathogenesis of T. vaginalis infection in vivo, may have important impli
204 ever having used a condom were predictive of T. vaginalis infection.
205 croscopy and culture and for the presence of T. vaginalis DNA by specific PCR of vaginal and urine sp
206                              Pretreatment of T. vaginalis with metronidazole or periodate abolished t
207                            The prevalence of T. vaginalis in this sample was 23.4% (105 of 449) by th
208                            The prevalence of T. vaginalis infection before HIV infection was 11.3% in
209                 Given the high prevalence of T. vaginalis infection in HIV-endemic areas, T. vaginali
210                          Thus, prevalence of T. vaginalis infection in men is underestimated if only
211 ettings with a moderately high prevalence of T. vaginalis infection, particularly when microscopy is
212                            The prevalence of T. vaginalis was 18.8% overall and 8.8% in the 307 wet-m
213                  Treatment and prevention of T. vaginalis infection could reduce HIV-1 risk in women.
214 hat GAPDH is a surface-associated protein of T. vaginalis with alternative functions.
215 entify a fibronectin (FN)-binding protein of T. vaginalis.
216                Given the significant rate of T. vaginalis detection, with age distribution analogous
217 rt addressing the differential regulation of T. vaginalis genes immediately upon contact with VECs.
218           The derived amino acid sequence of T. vaginalis LDH (TvLDH) was found to be more closely re
219  recently completed draft genome sequence of T. vaginalis provides an invaluable resource to guide mo
220                             The stability of T. vaginalis DNA in 40 urine samples was assessed by sto
221       Overall, there was better stability of T. vaginalis DNA when specimens were stored at 4 degrees
222 netic diversity, and population structure of T. vaginalis.
223  rate from other facilities exceeded that of T. vaginalis (7.2%; P = 0.004).
224 thesis of GAPDH by antisense transfection of T. vaginalis gave lower levels of organisms bound to FN
225 nt efforts in the diagnosis and treatment of T. vaginalis in women and men, especially in countries w
226 atural history, and response to treatment of T. vaginalis infection in adolescent women.
227                                 Treatment of T. vaginalis T016 with >/=20 mM 1,4-diamino-2-butanone (
228         Here, we review the existing data on T. vaginalis surface proteins and summarize some of the
229 rom extraurogenital sources, with a focus on T. vaginalis.
230 hibition of ornithine decarboxylase (ODC) on T. vaginalis.
231     An optimal analytical sensitivity of one T. vaginalis organism per PCR was achieved.
232 ions with C. trachomatis, N. gonorrhoeae, or T. vaginalis (women only) detected during 4 scheduled re
233 gnoses of C. trachomatis, N. gonorrhoeae, or T. vaginalis infections should return in 3 months for re
234 detect N. gonorrhoeae and C. trachomatis (or T. vaginalis if utilized), there is no US Food and Drug
235                   Moreover, 2 of these other T. vaginalis isolates are concurrently infected by strai
236                                     Overall, T. vaginalis, C. trachomatis, and N. gonorrhoeae prevale
237                     The trichomonad parasite T. vaginalis causes one of the most common non-viral sex
238 levels were lower in females with a positive T. vaginalis antigen test result, a vaginal pH >4.5, vag
239 N. gonorrhoeae infection overall, a positive T. vaginalis ASR result was a better predictor of concom
240 ected-patient status was defined as positive T. vaginalis test results by at least 2 assays.
241               The increased rate of positive T. vaginalis ASR results was observed in both point-of-c
242                               While positive T. vaginalis findings via direct saline preparation did
243 an interview and a pelvic exam, four primary T. vaginalis tests (wet mount, culture, a rapid test, an
244  found that T. vaginalis secretes a protein, T. vaginalis macrophage migration inhibitory factor (TvM
245  and virtually 100% identity to the reported T. vaginalis subunit.
246 the presence of a 5.5-kb double-stranded RNA T. vaginalis virus (TVV) was assessed.
247                             Highly sensitive T. vaginalis molecular ASR not only transcends issues of
248                                    The short T. vaginalis PFK shares a most recent common ancestor wi
249 re, we biochemically characterize the single T. vaginalis Tgs (TvTgs) encoded in its genome and demon
250  STI phenotype reflected detection of solely T. vaginalis (54.2% of all health care encounters that r
251  to identify a simple method for stabilizing T. vaginalis DNA in urine samples that could be easily a
252 ic and phylogenetic analyses determined that T. vaginalis population structure is strongly influenced
253                           We have found that T. vaginalis mRNAs are protected by a 5' cap structure,
254                           We have found that T. vaginalis secretes a protein, T. vaginalis macrophage
255                    It has been reported that T. vaginalis does not grow on sucrose.
256 r intracellular redox buffer by showing that T. vaginalis contains high levels of cysteine ( approxim
257                                          The T. vaginalis alpha-actinin amino acid sequence and the s
258                                          The T. vaginalis enzyme was most similar to PPi-PFK of the m
259                                          The T. vaginalis LPG triggered interleukin 8 (IL-8), which p
260                                          The T. vaginalis-specific probe contains a 5'-fluorescein (5
261 amblia POR than with POR of bacteria and the T. vaginalis hydrogenosome.
262 0, which was verified experimentally for the T. vaginalis AP33 adhesin.
263 , no significant difference was noted in the T. vaginalis detection rates (8.9 and 8.6%, P = 0.85).
264 ding in other PPi-PFKs were conserved in the T. vaginalis enzyme.
265 5 A/B, which target different regions in the T. vaginalis genome, and seven were determined to be fal
266                            Nevertheless, the T. vaginalis genome contains some 11 putative sucrose tr
267                            Comparison of the T. vaginalis alpha-actinin epitopes with proteins in dat
268 ns, respectively, while the 12-kDa FD of the T. vaginalis hydrogenosome was most similar to the 12-kD
269 ales (24.7 years) was lower than that of the T. vaginalis-infected females (mean, 30.1 years; P < 0.0
270  surface glycoconjugate of the parasite, the T. vaginalis lipophosphoglycan (LPG).
271  studies indicate that it interacts with the T. vaginalis RNAP II large subunit C-terminal domain.
272                                        Thus, T. vaginalis PNP (TvPNP) functions in the reverse direct
273 nted with symptoms of vaginitis, exposure to T. vaginalis, or multiple sexual partners.
274 action to alpha-actinin suggests exposure to T. vaginalis.
275  with the hypothesis that drug resistance to T. vaginalis resulted from a single or very few mutation
276 ng host inflammatory and immune responses to T. vaginalis are poorly understood.
277 ion prevalences were 1.3% for C. trachomatis/T. vaginalis, 0.61% for C. trachomatis/N. gonorrhoeae an
278 lity to transiently and selectably transform T. vaginalis should greatly enhance research on this imp
279 and the increased risk for HIV transmission, T. vaginalis infection should be reconsidered for inclus
280  adhesins between control versus DAB-treated T. vaginalis parasites.
281      Equally noteworthy was that DAB-treated T. vaginalis with enhanced adherence did not possess the
282                             After treatment, T. vaginalis DNA was undetectable within 2 weeks in all
283 the four primary tests was considered a true T. vaginalis-positive result.
284             A key difference between the two T. vaginalis sequences was that Arg91 of MDH, known to b
285 itivity for every additional day delay until T. vaginalis was first detected in cultures (odds ratio
286 ith no difference between urethral and urine T. vaginalis detection (P = 0.53).
287 ence and cytotoxicity were not observed when T. vaginalis was exposed to human vaginal fibroblasts or
288 se, and HIV-infection status associated with T. vaginalis infection.
289 locations were significantly associated with T. vaginalis infection.
290        VCU-M1, which is also associated with T. vaginalis.
291                            Coincubation with T. vaginalis isolates induced disruption of monolayer in
292             All sequences were colinear with T. vaginalis gap1 and shared with it as a synapomorphy a
293 epithelial cells or cell lines cultured with T. vaginalis was measured by monitoring transepithelium
294 A in vaginal fluids from women infected with T. vaginalis and uninfected controls.
295             Sera from patients infected with T. vaginalis are reactive to TvMIF, especially in males.
296 om 838 women, 116 of whom were infected with T. vaginalis, were analyzed.
297 nal fluids from pregnant women infected with T. vaginalis.
298 issues following intravaginal infection with T. vaginalis but were not seen in uninfected mice.
299               A total of 85.7% of males with T. vaginalis-positive pharyngeal collections indicated s
300    This rate was higher than those seen with T. vaginalis (9.0%; P = 0.005), C. trachomatis (6.2%), a

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top